Exact Sciences Corp. today announced the launch of the Riskguard hereditary cancer test in the U.S. The Riskguard test provides an individualized patient report that uses a blood or saliva sample to determine gene-specific and familial risks for 10 common cancers, including colorectal, breast, prostate, skin, ovarian, endometrial, pancreatic, gastric, kidney, and endocrine.
For patients already diagnosed with cancer, knowing about certain gene variants can help create individualized treatment plans. The Riskguard test also helps inform the risk stratification for patients who have a family history of cancer by identifying changes in cancer-associated genes. These actionable results help health care providers better understand their patients’ risk level and management options.
Exact Sciences’ customer care teams are available to help patients explore the testing process and understand possible results and outcomes. Genetic counselors are also available to help health care providers interpret results and review medical management options.
The Riskguard test is covered by Medicare and many commercial insurance plans for eligible patients. For more information on the Riskguard test, click here.
